Conference abstract · 25 Jan 2019
Conference abstractPublished 24 Sep 2015
Refractory GERD treatment
TARGID, Belgium
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
About 30-40 % of GERD patients fail to respond to conventional treatments (standard or double dose of proton-pump inhibitors (PPI), prokinetics, low dose antidepressants) and, despite the efforts of the pharmaceutical companies to rule out new drugs beneficially affecting reflux pathophysiology, their management give rise to a major medical problem. However, there are preclinical and preliminary clinical evidences on the usage of newer, both pharmacological and non-pharmacological, remedies in refractory GERD management. These remedies need an accurate updated reviewing work in order to give to the physician a clear snapshot of âÂ?Â?where are we nowâÂ? in GERD management (describing refractory GERD definition and differential diagnosis, and the issues arising from conventional therapies) and âÂ?Â?what we will doâÂ? about the most promising treatments for refractory GERD. This last issue is crucial because will condition the attention of physician towards some of newer remedies for this subset of patients, in synergy with the pharmaceutical industry. T.A.R.G.I.D. is the largest gastrointestinal translational laboratory across Europe that is a world referral center for the study of gastrointestinal motility, in general and of the GERD pathophysiology and treatment, in particular. According to my previous PhD program experience in and the actual collaboration with TARGID I will talk about: GERD definition and its physiopathology, refractory GERD definition and its pathophysiology issues, diagnostic flow-chart (including definition of overlap diseases and refractory GERD misdiagnosis (e.g. functional dyspepsia)), evidence-based therapeutic flow-chart including both pharmacological (older and newer PPI types and dosage, prokinetics, drugs affecting lower esophageal sphincter functioning) and non-pharmacological treatments (laparoscopic, endoscopic antireflux surgery), newer development directions in refractory GERD management.
Subjects
Gastroenterology & HepatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 25 Aug 2015
Refractory GERD Treatment
Perspective · 31 Jan 2024
Managing GERD: Lifestyle Strategies to Minimize Symptoms and Optimize Treatment Outcomes
Mini review · 3 Oct 2022
Analysis of the Literature on the Treatment of Refractory Pancreatic Fistula
Case report · 30 Jun 2020
Sustained Histologic Remission (Complete Mucosal Healing) 12 Years after One-Time Treatment of Refractory Ulcerative Colitis with Novel Combination Therapy: A Case Report
More from this journal
The newest in Journal of Gastrointestinal & Digestive System.
Research article · 1 Jan 2026
Prospective Observational Study for the Evaluation of Efficacy and Safety Profile of Probiotics Food Supplement in Children with Acute Diarrhea
Case report · 11 Nov 2025
Bitter Guard: A Gut Wrenching Surprise
Research article · 18 Jun 2025
Ursodeoxycholic Acid Treatment of LPAC Presenting as Post Cholecystectomy Pain: Rationale and Design of a Randomised Trial
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Gastrointestinal & Digestive System
- SubjectGastroenterology & Hepatology
- BylineArticles whose byline prints “Emidio Scarpellini”
